Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products

Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.

Reports

Displaying 1 - 10 of 103. 10 per page. Page 1.

Advanced Search

Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey

May 17, 2021
This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice. Related Products
ASPE Issue Brief

Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome Issue Brief

January 18, 2021
Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services
ASPE Issue Brief

Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 Issue Brief

January 18, 2021
Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services

Treatment for Opioid Use Disorder May Reduce Substantiated Cases of Child Abuse and Neglect

January 10, 2021
Buprenorphine treatment has been found to be an effective treatment for opioid use disorder (OUD). Child welfare systems have been partnering with treatment providers to increase access, yet little is known about its role in improving outcomes related to child maltreatment.
ASPE Issue Brief

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief

November 30, 2020
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services
ASPE Issue Brief

Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief

November 30, 2020
Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services

Medicare Part B Drugs: Trends in Spending and Utilization, 2006-2017

November 19, 2020
Medicare covers prescription drugs provided during inpatient hospital and skilled nursing facility stays through Part A, retail prescription drugs through Part D, and drugs provided in physicians’ offices and hospital outpatient departments through Part B. Over the 2006-17 period, Medicare FFS Part B drugs spending per enrollee grew at 8.1 percent annually.

Medicare FFS Part B and International Drug Prices: A Comparison of the Top 50 Drugs

November 19, 2020
The September 13, 2020 Executive Order on Lowering Drug Prices by Putting America First declared, “It is the policy of the United States that the Medicare program should not pay more for costly Part B or Part D prescription drugs or biological products than the most-favored-nation price.” The Most Favored Nation (MFN) Model issued by the Centers for Medicare & Medicaid Services (CMS) on No

Comparing Insulin Prices in the U.S. to Other Countries

September 23, 2020
Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach.

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care

July 8, 2020
Treatment providers, policymakers, and others are seeking ways to reverse the tide of mortality and morbidity that has accompanied the opioid epidemic. There are evidence-based treatments for opioid use disorder (OUD), including medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone. Research shows that retention in MAT results in better outcomes.